Samir, H., Shafik, S., Yahia, M., Mamdouh, N. (2015). EXPRESSION OF BONE MORPHOGENETIC PROTEIN- 2 UNDER SIMVASTATIN THERAPY AFTER CYCLOSPORIN -A- INDUCED ALVEOLAR BONE LOSS IN RATS. Alexandria Dental Journal, 40(1), 113-119. doi: 10.21608/adjalexu.2015.58745
H Samir; S Shafik; M Yahia; N Mamdouh. "EXPRESSION OF BONE MORPHOGENETIC PROTEIN- 2 UNDER SIMVASTATIN THERAPY AFTER CYCLOSPORIN -A- INDUCED ALVEOLAR BONE LOSS IN RATS". Alexandria Dental Journal, 40, 1, 2015, 113-119. doi: 10.21608/adjalexu.2015.58745
Samir, H., Shafik, S., Yahia, M., Mamdouh, N. (2015). 'EXPRESSION OF BONE MORPHOGENETIC PROTEIN- 2 UNDER SIMVASTATIN THERAPY AFTER CYCLOSPORIN -A- INDUCED ALVEOLAR BONE LOSS IN RATS', Alexandria Dental Journal, 40(1), pp. 113-119. doi: 10.21608/adjalexu.2015.58745
Samir, H., Shafik, S., Yahia, M., Mamdouh, N. EXPRESSION OF BONE MORPHOGENETIC PROTEIN- 2 UNDER SIMVASTATIN THERAPY AFTER CYCLOSPORIN -A- INDUCED ALVEOLAR BONE LOSS IN RATS. Alexandria Dental Journal, 2015; 40(1): 113-119. doi: 10.21608/adjalexu.2015.58745
EXPRESSION OF BONE MORPHOGENETIC PROTEIN- 2 UNDER SIMVASTATIN THERAPY AFTER CYCLOSPORIN -A- INDUCED ALVEOLAR BONE LOSS IN RATS
1- Master student at the Oral Biology Department, Faculty of Dentistry, Alexandria University
2- Professor of Oral Biology, Faculty of Dentistry, Alexandria University
3Professor of Histochemistry and Cell Biology, Medical Research Institute, Alexandria University
4Lecturer of Oral Biology, Faculty of Dentistry, Alexandria University
Abstract
Introduction: Cyclosporin-A- has been used as an immunosuppressant to prevent the rejection of organ transplants. However, alveolar bone loss is an important negative side-effect of this drug. Simvastatin, a hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is known to inhibit cholesterol biosynthesis. It has advanced effects on bone formation in vivo and in vitro. So, we evaluated the expression of BMP 2 after administration of simvastatin in cyclosporin -A-associated alveolar bone loss in rats. Objective: To evaluate the effect of simvastatin and cyclosporin -A- on Alveolar bone by investigating the expression of Bone Morphogenetic Protein -2 (BMP-2) using Immunohistochemical and Image analysis investigation methods. Materials and methods: 24 adult male albino rats were divided into 3 groups: Group I: control group; 4 rats, Group II: cyclosporine -A- group; 10 rats (10 mg/kg) daily subcutaneous injection, Group III: Cyclosporin –A /Simvastatin group; 10 rats, simvastatin was taken orally daily (20mg/kg/day). Two rats from the control group and 5 rats from each of the studied experimental groups (group II & III) were sacrificed on days 15 and 30 consecutively, and examined using Immunohistochemical method, and Image analysis. Results: Immunohistochemical results revealed strong expression of BMP 2 in osteoblasts, osteocytes after simvastatin administration and weak expression in CsA. The same results were statistically significant in Immunohistochemical Optical Density (IOD) results. Histomorphometrical analysis of bone volume showed a significant increase in bone volume in simvastatin group than CsA group, and significant decrease in CsA than control. Conclusion: we can conclude that Simvastatin counteract the adverse effect of CsA induced alveolar bone loss by induction of BMP 2 in osteoblasts and osteocytes that induced new bone formation.
View on SCiNiTO
Top